Mueller Martin, Wolfs Tim G A, Schoeberlein Andreina, Gavilanes Antonio W D, Surbek Daniel, Kramer Boris W
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA.
Department of Obstetrics and Gynecology, University Hospital Bern and Department of Clinical Research, University of Bern, Bern, Switzerland.
Mol Cell Pediatr. 2016 Dec;3(1):6. doi: 10.1186/s40348-016-0034-x. Epub 2016 Feb 11.
Perinatal complications in both term- and preterm-born infants are a leading cause of neonatal morbidities and mortality. Infants face different challenges in the neonatal intensive care unit with long-term morbidities such as perinatal brain injury and bronchopulmonary dysplasia being particularly devastating. While advances in perinatal medicine have improved our understanding of the pathogenesis, effective therapies to prevent and/or reduce the severity of these disorders are still lacking. The potential of mesenchymal stem/stromal cell (MSC) therapy has emerged during the last two decades, and an increasing effort is conducted to address brain- and lung-related morbidities in neonates at risk. Various studies support the notion that MSCs have protective effects. MSCs are an easy source and may be readily available after birth in a clinical setting. MSCs' mechanisms of action are diverse, including migration and homing, release of growth factors and immunomodulation, and the potential to replace injured cells. Here, we review the pathophysiology of perinatally acquired brain and lung injuries and focus on MSCs as potential candidates for therapeutic strategies summarizing preclinical and clinical evidence.
足月儿和早产儿的围产期并发症是新生儿发病和死亡的主要原因。婴儿在新生儿重症监护病房面临不同挑战，诸如围产期脑损伤和支气管肺发育不良等长期疾病尤其具有毁灭性。尽管围产期医学的进展增进了我们对发病机制的理解，但仍缺乏预防和/或减轻这些疾病严重程度的有效疗法。在过去二十年中，间充质干/基质细胞（MSC）疗法的潜力已显现出来，并且人们越来越努力地解决有风险新生儿的脑和肺相关疾病。各种研究支持MSC具有保护作用这一观点。MSC来源容易，在临床环境中出生后可能很容易获得。MSC的作用机制多种多样，包括迁移和归巢、生长因子释放和免疫调节以及替代受损细胞的潜力。在此，我们综述围产期获得性脑损伤和肺损伤的病理生理学，并着重探讨MSC作为治疗策略潜在候选者的情况，总结临床前和临床证据。
